Skip to main content
. 2019 Nov 29;19(23):5260. doi: 10.3390/s19235260

Figure 3.

Figure 3

(A) Schematic unlocking of the (1)/(2)-gated NMOFs and the release of Apixaban, in the presence of thrombin, via the separation of the duplex gates by the formation of aptamer-thrombin complexes. (B) Fluorescence spectra of the released Apixaban from the drug-loaded NMOFs upon treatment with variable concentrations of thrombin for a fixed time interval of 30 minutes: (a) 0 μM, (b) 0.25 μM, (c) 0.5 μM, (d) 0.75 μM, and (e) 1.0 μM. (C) Time-dependent fluorescence changes upon the release of Apixaban from the (1)/(2)-gated drug-loaded NMOFs in the presence of (a) thrombin, 1 μM, or (b) no thrombin added. (D) Fluorescence spectra of Apixaban released from the (1)/(2)-gated, drug-loaded, NMOF upon treatment for a fixed time interval corresponding to 30 minutes with (a) thrombin, 1 μM; (b) no thrombin added; (c) BSA, 1 μM; (d) hemoglobin, 1 μM; and (e) vascular endothelial growth factor (VEGF), 1 μM.